A large licensing payment from one of the biotech's partners drives revenue growth.
News & Analysis: Ionis Pharmaceuticals
IONS earnings call for the period ending March 31, 2019.
Information from competitors and a collaborator sent the high-flying biotech lower.
Sometimes the best future returns come from companies that have already shown themselves to be successful.
The biotech turned an operating profit in the fourth quarter thanks to revenue from partners.
IONS earnings call for the period ending December 31, 2018.
Fourth-quarter earnings exceed expectations.
Adding these biotech stocks to your portfolio could be a great New Year's resolution for aggressive investors.
Earnings per share will more than double for each of these specialty drugmakers.
With $2 billion in the bank, the biotech can afford to invest in the future.